Global RTD Sensor Market Report 2020-2025 by Technology, Future Trends, Opportunities, Top Key Players and more…

A new market study, titled “Global RTD Sensor Market Research Report 2020”, has been featured on WiseGuyReports.

PUNE, MAHARASTRA, INDIA, February 27, 2020 /EINPresswire.com/ — RTD Sensor Market

This report focuses on RTD Sensor volume and value at global level, regional level and company level. From a global perspective, this report represents overall RTD Sensor market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Diodes Incorporated
Honeywell Sensing and Productivity Solutions
TE Connectivity Measurement Specialties
US Sensor
Vishay Beyschlag
OMEGA Engineering
Applied Measurement & Control
Onset Computer Corp
Jumo
Kimo Instruments
SensorTemp
Thermo-Kinetics Company Limited

Request Free Sample Report at https://www.wiseguyreports.com/sample-request/5010482-global-rtd-sensor-market-research-report-2020

Segment by Regions
North America
Europe
China
Japan
South Korea

Segment by Type
Industrial Platinum Resistance Thermometers
Standard Platinum Resistance Thermometers
Secondary Standard Platinum Resistance Thermometers

Segment by Application
Consumer Electronics
Power Generation
Automotive
Petrochemical
Healthcare
Industrial
Others

Table of Content:
1 Report Overview
2 Global Growth Trends
3 Market Share by Key Players
4 Breakdown Data by Type and Application
5 United States
6 Europe
7 China
8 Japan
9 Southeast Asia
10 India
11 Central & South America
12 International Players Profiles
13 Market Forecast 2020-2025
14 Analyst's Viewpoints/Conclusions
15 Appendix

View Detailed Report at https://www.wiseguyreports.com/reports/5010482-global-rtd-sensor-market-research-report-2020

About Us:
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

NORAH TRENT
WISE GUY RESEARCH CONSULTANTS PVT LTD
+1 646-845-9349
email us here


Source: EIN Presswire

CANNSUN MEDHEL GROUP PLC ANNOUNCES LETTER OF INTENT WITH MALAYSIAN BASED COMPANY FOR PHARMACEUTICAL PRODUCT DISTRIBUTION

This is the first step of Cannsun Medhel Group to enter Asia. We believe the addressable ASEAN market of 660 Million plus potential patients is where we want to be positioned for expansion.”

— Greg Bealer

ATHENS, GREECE, February 26, 2020 /EINPresswire.com/ — Cannsun Medhel Group PLC ("Cannsun" or the "Company"), is pleased to announce it has entered into a binding letter of intent (“LOI”) dated February 25th, 2020 with Borealis Healthcare Sdn Bhd (“Borealis”) pursuant to which the parties will form a joint venture company for the distribution of medical devices, pharmaceuticals, health and wellness products of Cannsun Medhel within Malaysia, Singapore and other agreed Asian markets.

Transaction

a. Initial Structure of Transaction: Cannsun has acquired 25% interest in Borealis Healthcare Sdn Bhd (“JVCo”). In consideration of the support and obligations to be provided by the Cannsun Group to JVCo as described herein. Borealis will have rights to use the name Cannsun Medhel.

b. Business: The business of the COMPANY will be the sale of fully EU certified and EU GMP compliant non-cannabis and cannabis based medical devices, pharmaceuticals, healthcare and wellness products (the “Products”) in the Territory. The Parties may mutually agree to expand the “Business” to include (i) partial packaging and/or manufacturing of a portion of the Products and (ii) the growing, manufacturing and distribution of medical cannabis and related products in the Territory;

c. Territory: (i) Malaysia; (ii) Singapore and (iii) such other additional countries/territories to be mutually agreed by the Parties. Where necessary, the Business in each jurisdiction (country/territory) will be carried out by separate joint venture companies incorporated based on terms identical to the JVCo;

d. Exclusive JVCo Rights: JVCo shall have the sole and exclusive right to carry out the Business in the Territory including importing, distributing, sales and to act as the authorized representative for all present and future products of the Cannsun Group in the Territory.

Upon execution of the Definitive Agreements the expected closing of the transaction is mid April 2020.

“This is the first step of Cannsun Medhel Group to enter Asia. We believe the addressable ASEAN market of 660 Million plus potential patients is where we want to be positioned for expansion. The ASEAN market is the fastest growing economy and our partner is well established in the market. We see this being a great opportunity for both companies. The Medhel brand established 1918 in Greece has a history of quality Medicines and Botanicals, and with Borealis we can expand this legacy to the ASEAN market. We see a 2nd phase of manufacturing products in Malaysia for the ASEAN market in 2021.” commented Greg Bealer, Director of Finance.

About Borealis
First established in 2019, Borealis Healthcare Sdn Bhd is a registered Malaysian company based and located in Kuala Lumpur, Malaysia. Its co-founders and management team, comprising Canadian and Malaysian partners, have worked together for more than 15 years delivering significant projects and establishing key networks globally and within the South East Asia region.

This joint venture with Cannsun-Medhel moves Borealis Healthcare forward in achieving its objectives of assisting professional healthcare providers continue to improve the healthcare they can provide, by bringing established, new and emerging healthcare products and services to Malaysia, Singapore and the other ASEAN nations. Cannsun-Medhel, building on its 103 year foundation of extensive pharmaceutical experience, its current EU GMP pharmaceutical manufacturing infrastructure, and EU certified products, will bring new options for healthcare providers, and investment to the region. This has the potential to improve healthcare and the quality of life for millions of people in the ASEAN region.

About Medhel
First established in 1918 and now with new management and ownership, Cannsun is re-emerging as a science-led, global, healthcare company focused on leveraging its existing infrastructure and reputation in the manufacture and distribution of established healthcare products and pharmaceuticals, as well as building a vertically integrated cannabis and cannabinoid division. The Company currently distributes products to thousands of healthcare professionals and pharmacies in 21 countries. Our current projected growth will enable us to deepen and extend our reach, so that we can help people everywhere live better, healthier lives.

www.cannsunmedhel.com

Contact:

David Parry
Chief Executive Officer
Phone: +30 693 603 5933
Email: david@cannsun.com

Ross Burnstad
Co-Founder | Managing Director
Phone: +60 12 217 3364
Email: ross.burnstad@borealis-group.com

Greg Bealer
Director of Finance
Phone: +1 780 970 3789
Email: g.bealer@cannsun.com

David Parry
Cannsun Medhel Group PLC
+1 604-889-2188
email us here


Source: EIN Presswire

CANNSUN MEDHEL GROUP PLC ANNOUNCES LETTER OF INTENT WITH MALYASIAN BASED COMPANY FOR PHARMACEUTICAL PRODUCT DISTRIBUTION

This is the first step of Cannsun Medhel Group to enter Asia. We believe the addressable ASEAN market of 660 Million plus potential patients is where we want to be positioned for expansion.”

— Greg Bealer

ATHENS, GREECE, February 26, 2020 /EINPresswire.com/ — Cannsun Medhel Group PLC ("Cannsun" or the "Company"), is pleased to announce it has entered into a binding letter of intent (“LOI”) dated February 25th, 2020 with Borealis Healthcare Sdn Bhd (“Borealis”) pursuant to which the parties will form a joint venture company for the distribution of medical devices, pharmaceuticals, health and wellness products of Cannsun Medhel within Malaysia, Singapore and other agreed Asian markets.

Transaction

a. Initial Structure of Transaction: Cannsun has acquired 25% interest in Borealis Healthcare Sdn Bhd (“JVCo”). In consideration of the support and obligations to be provided by the Cannsun Group to JVCo as described herein. Borealis will have rights to use the name Cannsun Medhel.

b. Business: The business of the COMPANY will be the sale of fully EU certified and EU GMP compliant non-cannabis and cannabis based medical devices, pharmaceuticals, healthcare and wellness products (the “Products”) in the Territory. The Parties may mutually agree to expand the “Business” to include (i) partial packaging and/or manufacturing of a portion of the Products and (ii) the growing, manufacturing and distribution of medical cannabis and related products in the Territory;

c. Territory: (i) Malaysia; (ii) Singapore and (iii) such other additional countries/territories to be mutually agreed by the Parties. Where necessary, the Business in each jurisdiction (country/territory) will be carried out by separate joint venture companies incorporated based on terms identical to the JVCo;

d. Exclusive JVCo Rights: JVCo shall have the sole and exclusive right to carry out the Business in the Territory including importing, distributing, sales and to act as the authorized representative for all present and future products of the Cannsun Group in the Territory.

Upon execution of the Definitive Agreements the expected closing of the transaction is mid April 2020.

“This is the first step of Cannsun Medhel Group to enter Asia. We believe the addressable ASEAN market of 660 Million plus potential patients is where we want to be positioned for expansion. The ASEAN market is the fastest growing economy and our partner is well established in the market. We see this being a great opportunity for both companies. The Medhel brand established 1918 in Greece has a history of quality Medicines and Botanicals, and with Borealis we can expand this legacy to the ASEAN market. We see a 2nd phase of manufacturing products in Malaysia for the ASEAN market in 2021.” commented Greg Bealer, Director of Finance.

About Borealis
First established in 2019, Borealis Healthcare Sdn Bhd is a registered Malaysian company based and located in Kuala Lumpur, Malaysia. Its co-founders and management team, comprising Canadian and Malaysian partners, have worked together for more than 15 years delivering significant projects and establishing key networks globally and within the South East Asia region.

This joint venture with Cannsun-Medhel moves Borealis Healthcare forward in achieving its objectives of assisting professional healthcare providers continue to improve the healthcare they can provide, by bringing established, new and emerging healthcare products and services to Malaysia, Singapore and the other ASEAN nations. Cannsun-Medhel, building on its 103 year foundation of extensive pharmaceutical experience, its current EU GMP pharmaceutical manufacturing infrastructure, and EU certified products, will bring new options for healthcare providers, and investment to the region. This has the potential to improve healthcare and the quality of life for millions of people in the ASEAN region.

About Medhel
First established in 1918 and now with new management and ownership, Cannsun is re-emerging as a science-led, global, healthcare company focused on leveraging its existing infrastructure and reputation in the manufacture and distribution of established healthcare products and pharmaceuticals, as well as building a vertically integrated cannabis and cannabinoid division. The Company currently distributes products to thousands of healthcare professionals and pharmacies in 21 countries. Our current projected growth will enable us to deepen and extend our reach, so that we can help people everywhere live better, healthier lives.

www.cannsunmedhel.com

Contact:

David Parry
Chief Executive Officer
Phone: +30 693 603 5933
Email: david@cannsun.com

Ross Burnstad
Co-Founder | Managing Director
Phone: +60 12 217 3364
Email: ross.burnstad@borealis-group.com

Greg Bealer
Director of Finance
Phone: +1 780 970 3789
Email: g.bealer@cannsun.com

David Parry
Cannsun Medhel Group PLC
+1 604-889-2188
email us here


Source: EIN Presswire

Arizona Company Invents Technology that Kills COVID-19 in Hospital Patient Rooms

Nevoa’s smart disinfection technology uses Hypochlorous Acid to disinfect hospital patient rooms, killing pathogens such as COVID-19.

Nevoa’s smart disinfection technology uses Hypochlorous Acid to disinfect hospital patient rooms, killing pathogens such as COVID-19.

Technology invented in Tempe, Arizona, by Nevoa Inc., is designed to kill serious pathogens such as COVID-19 (coronavirus) in hospital patient rooms.

TEMPE, ARIZONA, USA, February 26, 2020 /EINPresswire.com/ — Nevoa® Inc., a Tempe, Arizona-based company, has invented a new disinfection technology for hospital patient rooms that has been proven to be 99.99% effective at killing bacteria and viruses that cause life-threatening infections, such as COVID-19 (coronavirus disease 2019), and other Healthcare Associated Infections (HAIs).

The technology has been used since July 2019 with great success at two Arizona hospitals that are part of a major, Phoenix-based health system. A study by the University of Arizona proved that Nevoa’s disinfection system, combined with modified manual room cleaning, was 300 times more effective at whole room disinfection than manual cleaning alone.

“While coronavirus is a hypersensitive topic right now due to its ability to spread rapidly, let’s also remember that 100,000 people in the U.S. die each year from Healthcare Associated infections,” said Ernest Cunningham, president of Nevoa Inc. “That’s about 275 people per day, which is why Nevoa created this disinfection technology.”

The disinfection system was developed locally and includes the Nimbus™ robot and Nevoa Microburst Solution™, whose active ingredient is Hypochlorous Acid (HOCl). Nimbus atomizes Microburst into a dense fog in a non-occupied patient room (after discharge). The disinfectant solution is distributed through the entire room with 100% surface contact, even on the undersides of equipment and the bed. The Nimbus robot then automatically begins a dehumidification process to remove all disinfectant solution from the room.

This cutting-edge technology kills the viruses and bacteria that reside on surfaces and cause illnesses, such as COVID-19. By eliminating these type of pathogens that exist in patient hospital rooms, the risk of viruses being transferred from person-to-person is significantly reduced.

Microburst is an EPA-registered, hospital-grade disinfectant. Its effectiveness was proven in a swab-sampling study conducted by an independent laboratory in Austin, Texas, in 2019. The study proved that the atomization of Nevoa’s Microburst Solution in hospital patient rooms was up to 99.9999% effective at eliminating deadly pathogens that can cause infections.

COVID-19 appears to be another severe respiratory virus that has arisen in recent years, following the outbreaks of SARS in 2003 and MERS in 2012. Nevoa has first-hand experience with killing evolved coronaviruses.

“Interestingly, COVID-19 is fairly easy to kill outside the body,” said Cunningham. “Feline Calicivirus (FCV) and Influenza A (H1N1) are much more difficult to kill, and these pathogens are used as surrogates to gauge effectiveness against viruses such as COVID-19, SARS and MERS. Our system is highly effective against those surrogates and others. We’re proud to have invented a highly effective solution to combat this healthcare problem.”

About Nevoa Inc.
Nevoa (https://nevoainc.com) was founded to invent disinfection products that eliminate HAIs and save the lives of people in environments where germs and pathogens are known to thrive. Nevoa’s mission is to transform the healthcare industry’s decades-old disinfection and cleaning protocols to highly-effective, automated protocols that clean better. To achieve major decreases in the HAI epidemic, Nevoa believes hospitals must embrace technology-based disinfection protocols that decontaminate hospital rooms after every patient discharge. Nevoa saves lives by engineering the most fiscally-, socially-, and environmentally-responsible disinfecting solutions for the healthcare industry, creating true, pathogen-free facilities.
###

Ernest Cunningham
Nevoa Inc.
+14803614071
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Professor Sergei Eremenko becomes Honorary Professor

Sergei Eremenko, Honorary Professor, 2020

Sergei Eremenko, Honorary Professor, 2020

Professor Sergei Eremenko, Australian-Ukrainian scientist, awarded the title of Honorary Professor of National Aerospace University 'Kharkiv Aviation Institute'

SYDNEY, NEW SOUTH WALES, AUSTRALIA, February 27, 2020 /EINPresswire.com/ — Sergei Eremenko, an Australian-Ukrainian scientist and author of three books, graduate of the National Aerospace University “Kharkiv Aviation Institute”, PhD, Doctor of Engineering, formerly one of the youngest professors in the world holding both an academic title and a position of a Professor, has been awarded the academic title of ‘Honorary Professor’.

EARLY LIFE

Sergei Eremenko graduated in 1986 with a degree in Applied Mathematics from the National Aerospace University, Kharkiv Aviation Institute in Ukraine. Upon being admitted to post-graduate PhD study, he started working on engineering, military and space projects with S.P. Korolev Rocket and Space Corporation Energia, Machine-Building Plant “Yuzhmash”, Kamov Helicopter Plant, Nikolaev Ship Building Plant, NPO “Turboatom”, and a few atomic power stations and heating systems plants. He developed computational models and software packages for the calculation of static and dynamic stress and thermal fields in engineering and space constructions based on variations, invented by him, of finite element methods – structural finite element and equilibrium boundary element methods.

A PHD AT 24

This fundamental and applied research led to a Ph.D. in Mechanical Engineering in 1988. Sergei started publishing his papers in major journals such as Mechanics of Composite Materials, Applied Mechanics, Applied Mathematics and Mechanics, all of which were later translated into English.

TWO BOOKS AT 27 AND 28

By this age, Sergei had authored two books. Remarkably, his first book “Finite Element Methods in Solid Mechanics” (”Методы конечных элементов в механике деформируемых тел”, https://books.google.com.au/books?id=dyTLDwAAQBA) written at the age of 27, has been widely used for almost 30 years as a text book, referenced in hundreds of (Russian) Google searches, scientific papers and dissertations. The book is included in many libraries in countries including Ukraine, Russia, Belarus, Kazakhstan, Armenia and in foreign libraries including the United States, Germany and the Netherlands.

His second Book “Natural Vibrations and Dynamics of Composite Materials and Constructions” (in Russian)
https://books.google.com.au/books?id=a9jMDwAAQBAJ was dedicated to the complex problems of vibrations of rocket composite materials.

DOCTOR OF ENGINEERING AT 29, PROFESSOR AT 31

Continuing with passion and drive, Sergei defended his second thesis in mathematical simulation and mechanical engineering at 29, in the first year of post-doctoral study. After receiving his formal diploma of the academic title of professor in 1995 from the Ministry of Education of Ukraine, he was offered the position of Professor at Kharkiv National University of Construction and Architecture where he taught for many years.

Sergei held both the formal academic title and position of a University professor. Also, Sergei received the honour of becoming a Leading Research Fellow at the Institute for Problems in Machinery of the National Academy of Sciences of Ukraine.

SERGEI EREMENKO AND HIS TEACHER

In 1984, Sergei met his teacher and co-author Academician V.L. Rvachev who became the mentor of his second doctoral thesis. The famous Ukrainian Academician and mentor of 70 PhD and 25 professors, V.L. Rvachev became ‘the lifetime inspiration’ for Sergei, who dedicated many of his papers to his teacher’s memory, including a special memorial tribute article https://www.researchgate.net/publication/322818484.

MIGRATION TO AUSTRALIA

In 1997, Sergei and his family migrated to Sydney, Australia. Sergei opened a new chapter in his life by launching his career by establishing company Soliton Scientific and consulting in Science and Technology, IT, Data Science, Artificial Intelligence and Machine Learning. For more than 20 years Sergei has been offering his expertise to international giants such as Hewlett-Packard, Fujitsu, Fuji Xerox and major Australian companies including ANZ Bank, ABC, Towers, Challenger, TABCORP, and HCF Insurance.

His love for fundamental science continues as an independent researcher. His field of research has expanded to the observations and theory of solitons, nonlinear solitonic models and trading robots for financial markets, models of spacetime and matter quantization based on AString atomic functions, and atomic machine learning published in a few papers and a new book (https://www.researchgate.net/profile/Sergei_Eremenko).

His current applied research revolves around the popular domains of Artificial Intelligence and Machine Learning. After receiving his Machine Learning certifications from Stanford and Microsoft, Sergei is passionate about building smart Machine Learning models for financial markets, insurance and health, potentially benefiting millions of people around the world. Dedicated to sharing his knowledge, Sergei has lectured in Machine Learning at The University of Technology of Sydney and at HCF Insurance.

THIRD BOOK

In 2019, Sergei launched his third book – this time of popular science – ‘Soliton Nature: Discover Beautiful Nature with 200 images and video channel’ https://www.amazon.com/Sergei-Eremenko/e/ B082F3MQ4L accompanied by a YouTube Video Channel https://www.youtube.com/channel/UCexT5iyczZH2HY1-jSafFeQ and an interactive Web Site www.solitonnature.com. This new book, positively reviewed by scientists in Australia, UK, Russia, and Ukraine, is dedicated to the magnificent nonlinear natural phenomena of solitary, grid, envelope waves, breathers, tsunamis, twisters, and others.

KEEPING CONNECTIONS WITH HIS UNIVERSITY

Being in Australia, Sergei has been keeping up his connections with his alma-mater – the National Aerospace University, providing his memorabilia to the University Anniversary Book ‘Times and People’ where Sergei is mentioned as a famous university graduate (https://k304.khai.edu/pub/2018/02/history2018.pdf).

HONORARY PROFESSOR

In 2019, Sergei was invited to do a scientific presentation to the open seminar of the Department of Informatics at the National Aerospace University, which recommended Sergei be honoured with an honorary title.

By anonymous voting, on the University Scientific Council on 20-Feb-2020, Sergei was awarded the academic title of ‘Honorary Professor’ of the National Aerospace University 'Kharkiv Aviation Institute’ (https://www.researchgate.net/publication/339499501).

CONTACTS

Sergei can be contacted via
– LinkedIn https://www.linkedin.com/in/sergei-eremenko-3862079/,
– Facebook https://www.facebook.com/SergeiEremenko.Author/,
– ResearchGate https://www.researchgate.net/profile/Sergei_Eremenko,
– web site www.solitonnature.com,
– Video Channel https://www.youtube.com/channel/UCexT5iyczZH2HY1-jSafFeQ, and
– Amazon Authors https://www.amazon.com/Sergei-Eremenko/e/B082F3MQ4L.

Soliton Scientific
Soliton Scientific
+61 413 041 125
email us here
Visit us on social media:
Facebook
LinkedIn


Source: EIN Presswire

CSEM strengthens relationship with Morphotonics by ordering nanoimprint equipment

Renowned Swiss institute CSEM has ordered from Morphotonics roll-to-plate pilot & small volume production equipment capable of producing freeform optics devices

VELDHOVEN, NOORD-BRABANT, NETHERLANDS, February 26, 2020 /EINPresswire.com/ — CSEM strengthens relationship with Morphotonics by ordering nanoimprint equipment
Neuchâtel, Switzerland & Veldhoven, the Netherlands – February 25, 2020 – Renowned Swiss research and technology organization CSEM has ordered from Morphotonics roll-to-plate piloting & small volume production equipment capable of producing free-form optics devices.

The exponential growth of miniaturized optical components for a variety of applications demands for robust free-form micro-optics. To address this current market reality, the European PHABULOuS project (Pilot-line providing highly advanced & robust manufacturing technology for optical free-form μ-structures) was launched in January 2020 under CSEM’s leadership with the participation of 19 partners along the manufacturing value chain, including Morphotonics. Installing the large area substrate nano imprinting facility at CSEM by Morphotonics strengthens this endeavor even further.

Dr. Rolando Ferrini (CSEM Sector head & Project Coordinator for PHABULOuS):
“CSEM is extremely glad to have found in Morphotonics a competent and highly dedicated partner in roll-to-plate (R2P) UV imprint on large area substrates, which substantially complement its long standing competences in wafer scale UV replication. This will enable CSEM to better respond to customer’s requests in large area micro and nano UV replication. In particular, building a close collaboration between Morphotonics and CSEM, as reference Research and Technology Organization (RTO) for the large area R2P manufacturing of next generation free form micro optical components will be an asset for the recently born pilot line for the manufacturing of free form optical micro optics, PHABULOuS, funded under the H2020 framework program.“

Dr. Onno Lint (CEO of Morphotonics B.V.):
“We are extremely pleased that Swiss top-technology institute CSEM buys Morphotonics’ roll-to-plate technology as the new standard in large area nanoimprinting. We look forward to supporting CSEM’s strong expertise in micro-optics, lacquers and applications with our piloting equipment enabling low product cost and high throughput. This opens the door and paves the way for many commercial applications not previously conceptualized or economically feasible, ranging from new display technologies, novel lighting concepts and highly efficient solar solutions to life science products”.

About PHABULOuS
The PHABULOuS consortium consists of 19 Companies and RTOs along the whole manufacturing value chain and has received funding from the European Union’s Horizon 2020 research and innovation program under the Grant Agreement nº 871710, in Public Private Partnership with Photonics 21.

About CSEM:
CSEM, Founded in 1984, is a Swiss Research and Technology Organization (public-private partnership) specializing in microtechnology, nanotechnology, microelectronics, system engineering, photovoltaics, and communications technologies. Around 500 highly qualified employees work for CSEM in Neuchâtel, Zurich, Muttenz, Alpnach, and Landquart; each with a passion to help our partners achieve success in this rapidly evolving world.

About Morphotonics B.V.:
Morphotonics develops and sells unique roll-to-plate (R2P) production technology for imprinting nano- or microstructures on large area substrates. This OEM imprint equipment and consumables enable mass production of nano- or micropatterns at low cost and high optical precision. Morphotonics serves the market introduction of new consumer products in the display, automotive, lighting and solar industries. Morphotonics R2P production technology has been adopted by leading customers in Europe, United States and Asia.

For more information please contact:

CSEM
Dr. Rolando Ferrini
Sector Head
+41 79 950 24 69
rolando.ferrini@csem.ch
www.csem.ch

Morphotonics B.V.
Dr. Onno Lint
CEO
+31 6 300 64 916
onno.lint@morphotonics.com
www.morphotonics.com

Onno Lint
Morphotonics
+31 6 30064916
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Janssen Pharmaceutical exclusive interview released ahead of Pre-filled Syringes East Coast

Pre-filled Syringes East Coast

Pre-filled Syringes East Coast 2020

SMi Reports: Alie Jahangir from Janssen Pharmaceutical to speak at Pre-Filled Syringes East Coast returning to Boston USA, in April.

LONDON, UNITED KINGDOM, February 26, 2020 /EINPresswire.com/ — With SMi’s highly sought after Pre-Filled Syringes East Coast conference taking place on April 27th and 28th for its 7th year in Boston, the event is guaranteed to bring together specialists within the industry to provide an exclusive insight into the sphere of regulation, new digital technology trends, human studies and innovative design and delivery systems within the prefilled syringe industry and more.

Ahead of the conference, SMi Group has caught up with Janssen Pharmaceutical’s Senior Manager, Alie Jahangir to discuss his insight and on the Pre-filled syringes market as well as his presentation on day-one of the two-day conference.

For those interested in attending, there is a $200 Early Bird discount on bookings expiring on February 28th, 2020. Places can be reserved at www.pfsamericas.com/einpr7

Snapshot of Alie’s interview:

What current topic will you be addressing in your presentation and what would you say makes it relevant to 2020?

“My talk will be focusing on new stability paradigm for combination products, including PFS as single-entity CP/ The major challenges in this industry for manufacturers, as indicated earlier, includes the interaction of PFS with the drug products. This causes great concern because it creates stability issues. Manufacturers need to eliminate the interaction between drugs and packaging materials. Regulatory bodies companies and customers will scrutinize and look carefully at every aspect of needle and syringe is specially as they are being used more and more today. Processing and quality control issues are therefore important period manufacturing costs are rising specially because of growing concern of needle stick injuries. Safety measures to eliminate needle stick injuries are major concern in the health care…”

How would you like to see the PFS USA market developing in the future and where do you think the biggest growth area will be in 2020?

“Given the advances in biologic market and specific requirement of such class of therapeutic products vis a vis volume and viscosity, a closer collaboration between therapeutic and device makers would create more opportunities to meet patients’ unmet needs. The biggest growth area would be in the area of wearables…”

The full interview, event details and speaker line-up are available to download on the website. The brochure can we downloaded at www.pfsamericas.com/einpr7

Pre-filled Syringes East Coast
Conference: April 27th-28th 2020
Post-conference workshop Day: April 29th

Sponsored by:
Almac | Aptar Pharma | Bold insight | CSS | Credence MedSystems | Mitsubishi Gas Chemical | Owen Mumford | PHC Corporation | Polyplastics-Topas | Steris | Weiss-Aug | Zeon Speciality Materials | Zwick Roell |
Contact Information:
For all media inquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk

—ENDS—
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Jinna Drug Sidhu
SMi Group
02078276088
email us here


Source: EIN Presswire

Validation Consultant Connie Curts to be Featured on Close Up Radio

LEE'S SUMMIT, MISSOURI, UNITED STATES, February 26, 2020 /EINPresswire.com/ — Regulations compel due diligence to protect the public. Under FDA regulations, all healthcare related hardware, software, and instrumentation must go through a series of procedures to ensure it works consistently, accurately, can provide reliable raw data, and has strong electronic security to prevent changes or deletions. The combination of regulated procedures is referred to as “validation.”

Connie Curts is a validation consultant. She specializes in developing validation documentation for FDA-regulated equipment dedicated to pharmaceutical research.

“Everything that goes into a study to develop pharmaceuticals needs to be accurate, so all procedures must be followed specifically without deviation,” says Connie. “What I do is create the documents to define the intended usage for clients. There are user requirements against which you'd test the system to determine its accuracy. I create those test protocols, somebody else executes those protocols, and yet another person is reviewing the results to make sure the system demonstrates its performance.”

An IT professional by trade with a background in engineering, Connie develops the documentation for completeness and clarity, so clients know what they need to do to remain in compliance and everything is handled consistently and tracked through chain of custody.

“It's a tremendously complicated process, which is partly why drugs, especially new drugs, are so expensive,” says Connie. “With validation, you have to be very careful because in the long run, as with everything in health care, a patient's life could be at stake.”

When the FDA comes in and does an audit of a new system, they want to see all necessary due diligence.

“Sometimes it can be contentious with the FDA,” says Connie, “but I tend to believe that most people really are trying to do their best and be as detailed and accurate as possible. They are as concerned for the patient as much as anyone.”

Connie says she has always been fascinated by mathematics. She holds a bachelor's degree in electronics engineering technology through Missouri Institute of Technology. As the computer age changed and industries changed, her career evolved to focus on regulations in one industry.

“I prefer to tinker with things, make them work, debug them,” says Connie. “I also love teaching and giving back to the next generation, everything I could about my experiences and best practices for good laboratory procedure.”

She was one of 95 international collaborators on the book entitled Computerized Systems Used in Nonclinical Safety Assessment: Current Concepts in Validation and Compliance.

Close Up Radio will feature Connie Curts in an interview with Jim Masters on February 28th at 2pm EST

Listen to the show on BlogTalkRadio

If you have any questions for our guest, please call (347) 996-3389

Lou Ceparano
Close Up Radio
+1 (631) 850-3314
email us here
Visit us on social media:
Facebook


Source: EIN Presswire

PERTHERA AND LAZAREX CANCER FOUNDATION ANNOUNCE PARTNERSHIP TO ADVANCE PRECISION ONCOLOGY INITIATIVES

Lazarex and Perthera unite to advance Clinical Trial Access and Enrollment for Cancer Patients

HOLLISTON, MA, USA, February 26, 2020 /EINPresswire.com/ — Perthera, Inc., a Biohealth Informatics company with an Oncology Platform proven to advance patient outcomes, and Lazarex Cancer Foundation, an advocacy group whose mission is to improve patient access to cancer clinical trials, have announced the launch of their partnership today. Together, they will be focused on matching and enrolling patients in clinical trials through Lazarex’s IMPACT and CARE programs, by utilizing Perthera’s treatment-matching Artificial Intelligence (AI) technology and other elements of the Perthera Platform to advance precision medicine for cancer patients.

“We are excited to work with Lazarex Cancer Foundation, a leading organization dedicated to advancing and accelerating patient enrollment in clinical trials,” said Gary Gregory, CEO of Perthera, Inc. “Lazarex’s passion and mission align perfectly with our innovative technology Platform. Together, we form a powerful team to make a difference for patients, physicians and clinical trial sites.”

Perthera’s proprietary AI technology allows physicians to utilize comprehensive patient informatics, such as medical history and molecular profile information, to equip physicians with precisely matched therapies that are best suited to advance patient outcomes. Through Perthera’s partnership with Lazarex, patients will be matched to the most relevant clinical trials, while expanding patient access and clinical trial enrollment.

"Perthera’s Platform has been proven to advance patient outcomes from both an overall and progression-free survival perspective, and also proven to accelerate Clinical Trial enrollment by five times the national average,” said Dana Dornsife, Founder and Chairman of Lazarex Cancer Foundation. “Perthera’s exceptional capabilities are aligned with the broad reach of our CARE and IMPACT programs and this positions both organizations to deliver exemplary value to patients, physicians and our clinical trial sites across the country.”

According to the Journal of the National Cancer Institute, only 2%-4% of newly diagnosed patients participate in clinical trials. Unfortunately, finances and transportation tend to be the largest barriers in the way of these enrollments. Forbes notes that because of low enrollment, many clinical trials do not meet their targets, resulting in a significant barrier to the advancement of cancer research. Lazarex, founded by members who recognized this significant issue, provides education to patients and has created supportive programs to promote higher patient enrollment in clinical trials.

Perthera’s partnership with Lazarex aims to utilize its proven, proprietary Platform to increase clinical trial enrollment and generate real-world evidence to advance cancer research & development. To reach out to Perthera regarding their Platform and matched treatment recommendations for oncologists and patients, contact Hope@Perthera.com or call (833) 781-7810.

If you are a cancer patient, a caregiver or friend of a cancer patient interested in patient resources or learning more about the possibility of participating in a clinical trial, visit the Lazarex Cancer Foundation’s website to learn more about your options https://lazarex.org/.

About Perthera, Inc.
Perthera is the leading Therapeutic Intelligence company advancing cancer care outcomes through its Precision Oncology Platform. Their innovative technology precisely matches cancer patients with ranked therapeutic options and has been utilized at over 250+ cancer care sites and utilized by over 10% of US Oncologists. Their Precision Oncology Platform, with an AI-driven Therapeutic Intelligence Engine™, has been clinically proven to extend overall and progression-free survival rates by over two-fold for cancer patients. Perthera positions Hospitals and Physicians to harness the power of Precision Medicine to improve patient outcomes and save lives. The Perthera Platform also offers a highly comprehensive Precision Cancer database and an array of services that delivers significant value to Pharma, Drug Development, Clinical Research Organizations and Payers.

About Lazarex Cancer Foundation
Lazarex Cancer Foundation is a publicly funded 501(c)(3) charity focused on the improvement of outcomes in cancer care, giving hope, dignity, and life to advanced-stage cancer patients and the medically underserved by providing assistance with costs for FDA clinical trial participation, identification of clinical trial options, community outreach and engagement. In its 14 years, Lazarex has assisted over 5,500 patients in clinical trials.
Learn more about Lazarex at https://lazarex.org/. For any media inquiries about the Lazarex Foundation, contact Laura Evans Manatos at +1.301.379.6028 and Laura@LauraEvansMedia.com.

Gary L. Gregory
Perthera, Inc.
+1 508-397-8885
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Oncology Biosimilar Market Size to be Worth 13,993.64 Million by 2024 – Zion Market Research

Oncology Biosimilar Market

Oncology Biosimilar Market

Oncology Biosimilar Market expected to generate revenue of around USD 13,993.64 million by end of 2024, growing at a CAGR of around 26.8% between 2018 and 2024

Oncology Biosimilar Market To Report Impressive Growth, Revenue To Surge To US$ 13,993.64 Million By 2024”

— Zion Market Research

NEW YORK, NEW YORK, UNITED STATES, February 26, 2020 /EINPresswire.com/ — Zion Market Research has published a new report titled “Oncology Biosimilar Market by Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, and Others), By Drug Type (mAb, Immunomodulators, Hematopoietic Agents, G-CSF, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacy, and Online Pharmacy): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024”. According to the report, global oncology biosimilar market was valued approximately USD 2655.19 million in 2017 and is expected to generate revenue of around USD 13,993.64 million by end of 2024, growing at a CAGR of around 26.8% between 2018 and 2024.

Biosimilar is the identical copy of oncology biologics used for the treatment of cancer and officially approved for the treatment of cancer. These molecules are cost-effective, efficient, and have the same ability as biologics. These molecules are easy to manufacture as compared to biologics and can only be manufactured after patent expiry. Earlier there were various patented biologics available in the market but nowadays most of the patents have expired and few are on the verge of patent expiry. In the past few years, various biosimilars have been approved by FDA for the treatment of various types of cancer such as blood cancer, colorectal cancer, breast cancer, and others. In the near future, it is expected that a few more biosimilars will be introduced in the market thus supporting the growth of the market.

Get Free Research Report Sample PDF – https://www.zionmarketresearch.com/requestbrochure/oncology-biosimilar-market

Oncology biosimilar market is primarily driven by the increased prevalence of cancer, which has led to the increased demand for affordable therapies for the treatment of cancer. There are various pharmaceutical companies available in the market which are involved in the manufacturing of biosimilar. Patent expiry is also one of the major driving factors for the oncology biosimilar market. Patent expiry will provide an opportunity to the pharmaceutical companies to manufacture more biosimilars which will fuel the market growth in the near future. Increased demand for the healthcare facilities and rapid approval of biosimilars will support the growth of oncology biosimilar market in the near future.

Oncology biosimilar market is segmented on the basis of different types of cancer such as breast cancer, colorectal cancer, blood cancer, neutropenia cancer, non-small cell lung cancer, and others. On the basis of drug type, the market is segmented into mAb, immunomodulators, hematopoietic agents, G-CSF, and others. G-CSF is expected to grow at the fastest rate in the global market over the forecast period. On the basis of the distribution channel, the market is segmented into retail pharmacies, hospital pharmacy, and online pharmacy. Hospital pharmacy is expected to grow at the fastest rate over the forecast period.

Browse full Report TOC for more Industry Insights – https://www.zionmarketresearch.com/toc/oncology-biosimilar-market

North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are key regional segments of global oncology biosimilar market. North America is anticipated to remain the leading region over the forecast period. Demand for oncology biologics was highest in North America especially in the U.S. Asia Pacific is expected to be the fastest growing region in the oncology biosimilar market during the forecast period. Moreover, the Middle East and Africa and Latin America are also expected to show considerable growth for this market in the years to come.

Some of the key players in oncology biosimilar market include Teva Pharmaceutical Industries Ltd., Biocon, STADA Arzneimittel AG, Sandoz International GmbH, Intas Pharmaceuticals Ltd., Celltrion Inc., Pfizer Inc., Apotex Inc., Dr. Reddy’s Laboratories Ltd., and BIOCAD, among others.

This report segments the global oncology biosimilar market as follows:

Global Oncology Biosimilar Market: Test Type Segment Analysis:

Breast Cancer
Colorectal Cancer
Blood Cancer
Neutropenia Cancer
Non-Small Cell Lung Cancer
Others

Global Oncology Biosimilar Market: Drug Type Segment Analysis:

mAb
Immunomodulators
Hematopoietic Agents
G-CSF
Others

Global Oncology Biosimilar Market: Distribution Channel Analysis:

Retail Pharmacies
Hospital Pharmacy
Online Pharmacy

Global Oncology Biosimilar Market: Regional Analysis:

North America
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa

Browse Press Release: https://www.zionmarketresearch.com/news/oncology-biosimilar-industry

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

Kalpesh Deshmukh
Zion Market Research
+1 855 465 4651
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire